2233507

Sbir Phase I: A Low-Cost, Bacterial Production Platform for the Manufacturing of High Purity Recombinant Proteins and Growth Factors -The Broader/Commercial Impact of This Small Business Innovation Research (SBIR) Phase I Project Is to Introduce a Cost-Effective Way to Produce Recombinant Proteins and Growth Factors for the Cultivated Meat Industry.

Cultivating Animal Cells to Create Animal Tissues, Including Muscle and Fat, Allows Manufacturers to Create Real Animal Meat as an Alternative to Animal-Farmed Meat. Producing Meat in This Method May Provide a Healthier, Safer, and More Ethical Source of Real Animal Meat. This Manufacturing Process Avoids Industrial Animal Farming and Consequently Uses Significantly Less Land and Water. It Also Avoids the Greenhouse Gases Emitted by Industrial Animal Farming and May Emit Far Fewer Greenhouse Gases.

Cultivated Meat Could Result in a Healthier Public as Well Since Its Controlled Production Will Likely Result in Fewer Foodborne Illnesses and Avoid the Cramped Conditions of Industrial Animal Farms That Can Breed New Illnesses. The Ability to Grow Meat in Nearly Any Location Increases the Nation's Food Supply Chain Resilience and Reduces Dependence on Foreign Food Imports. Finally, by Reducing the Amount of Industrial Animal Farms, Cultivated Meat Reduces the Need for Animal Slaughter.

The Proposed Project Will Demonstrate the Ability of the Innovation to Solve Several Challenges in the Current Production of Recombinant Proteins and Growth Factors in Traditional Protein Manufacturing Platforms That Prevent Manufacturing at Lower Costs and with High Purity. Cultivated Meat Has the Potential to Disrupt the >$1 Trillion Meat Industry, but the Ability to Source High Purity, Cheap Proteins Limits the Commercial Adoption of Cultivated Meat Products. The Innovation Could Produce Proteins at Cheaper Costs Than Existing Platforms Because It Bypasses Expensive and Time-Consuming Operational Manufacturing Steps While Still Achieving High Purity.

The Critical Technical Objectives of This Project Include:
1) The Establishment and Comparison of a Production Benchmark for Recombinant Growth Factor Production Against the Current Industry Standards,
2) The Optimization of the Growth Conditions Necessary for the Protein Production Platform to Achieve Improved Yields, and
3) The Creation of a Manufacturing Platform Optimization Toolkit to Increase the Quality and Amount of Usable Protein Produced.

The Knowledge Gained at the Completion of This Project May Provide Valuable Insights Into the Ability and Conditions to Promote High Production Levels of Proteins and Growth Factors While Providing Data Illustrating the Improvement When Compared Against Current Industry Standards.

This Award Reflects NSF's Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.

Opera Bioscience

47.084 - NSF Technology, Innovation, and Partnerships

National Science Foundation (NSF)

Evanston, Illinois 60201-3149 United States

Single Zip Code

None